CCO Independent Conference Coverage

Slides:



Advertisements
Similar presentations
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Advertisements

A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
May 29 - June 2, 2015 Borealis-1: Apatorsen + Gemcitabine/Cisplatin for Pts With Advanced Bladder Cancer CCO Independent Conference Highlights of the 2015.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December 5-8, 2015, Orlando, Florida ARRAY : Phase II Trial of Carfilzomib.
POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
CCO Independent Conference Coverage
CCO Independent Conference Coverage
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
CCO Independent Conference Highlights
KEYNOTE-045: Updated Survival Analysis of Phase III Trial of Pembrolizumab vs Paclitaxel, Docetaxel, or Vinflunine in Pts With Advanced Urothelial Carcinoma.
CCO Independent Conference Highlights
MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy CCO Independent Conference.
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.
CCO Independent Conference Highlights
: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma
KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer
Phase II HALO-202: nab-Paclitaxel and Gemcitabine ± PEGPH20 in Untreated Metastatic Pancreatic Ductal Adenocarcinoma CCO Independent Conference Highlights*
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.
CCO Independent Conference Coverage
Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
CCO Independent Conference Highlights
CCO Independent Conference Highlights
Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC CCO Independent Conference Highlights* of.
CCO Independent Conference Coverage
CCO Independent Conference Coverage
CCO Independent Conference Coverage
CCO Independent Conference Highlights
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
CCO Independent Conference Coverage
Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.
CCO Independent Conference Highlights
CCO Independent Conference Coverage
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
CCO Independent Conference Highlights
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
SOLO2: Safety, HRQoL With Maintenance Olaparib in Germline BRCA-Mutated Platinum-Sensitive Relapsed Serous Ovarian Cancer CCO Independent Conference Highlights*
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML New Findings in Hematology: Independent.
CCO Independent Conference Coverage
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
LOTUS: Investigation of Ipatasertib, a Novel Akt Inhibitor, in Combination With Paclitaxel as Frontline Therapy for Metastatic TNBC CCO Independent Conference.
New Findings in Hematology: Independent Conference Coverage
Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment CCO Independent Conference Coverage* of the 2016.
SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*
KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
Phase III PROUD-PV: Ropeginterferon α-2b Noninferior to Hydroxyurea in Polycythemia Vera New Findings in Hematology: Independent Conference Coverage of.
Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CCO Independent Conference Coverage
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
CCO Independent Conference Coverage
CCO Independent Conference Coverage
CheckMate 204: Nivolumab + Ipilimumab in Pts With Advanced Melanoma and Asymptomatic, Untreated Brain Metastases CCO Independent Conference Highlights*
Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO.
CCO Independent Conference Highlights
New Findings in Hematology: Independent Conference Coverage
New Findings in Hematology: Independent Conference Coverage
Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC CCO Independent Conference Highlights*
Baselga J et al. SABCS 2009;Abstract 45.
Presentation transcript:

Fulvestrant ± Palbociclib in ER+/HER2- Breast Cancer: An Extended Follow-up of PALOMA-3 CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. ER, estrogen receptor. This program is supported by educational grants from Genentech and Novartis.

PALOMA-3: Background Standard-of-care therapy for pts with ER+ and/or PgR+ breast cancer includes selective ER modulators and aromatase inhibitors Overexpression of CDK-4/6 associated with proliferation of ER+ and/or PgR+ breast cancer Palbociclib: first-in-class, oral, selective CDK-4/6 inhibitor PALOMA-3: randomized, double-blind, placebo-controlled phase III trial of fulvestrant + palbociclib vs fulvestrant + placebo in ER+/HER2- metastatic breast cancer after progression on endocrine therapy Fulvestrant + palbociclib associated with significantly longer PFS than control arm; trial ended at interim analysis by DSMB[1] Current report: longer-term safety, efficacy, and subgroup analyses from PALOMA-3[2] DSMB, data and safety monitoring board; ER, estrogen receptor; PgR, progesterone receptor. 1. Turner NC, et al. N Engl J Med. 2015;373:209-2129. 2. Cristofanilli M, et al. SABCS 2015. Abstract P4-13-01. Slide credit: clinicaloptions.com

PALOMA-3: Phase III Study Design Stratified by visceral metastases (yes/no), sensitivity to previous endocrine therapy, menopausal status Palbociclib 125 mg QD 3 wks on/1 wk off + Fulvestrant 500 mg IM Q4W (n = 347) Pts with HR+/HER2- MBC; PD after endocrine therapy; ≤ 1 chemotherapy regimen for advanced BC (N = 521) Tx to PD, toxicity, or study withdrawal Placebo 3 wks on/1 wk off + Fulvestrant 500 mg IM Q4W (n = 174) BC, breast cancer; CBR, clinical benefit rate; CR, complete response; HR, hormone receptor; MBC, metastatic breast cancer; PD, disease progression SD, stable disease; Tx, treatment. Primary endpoint: investigator-assessed PFS Secondary endpoints: ORR, CBR (CR, PR, or SD for ≥ 24 wks), OS, pt-reported outcomes, safety Slide credit: clinicaloptions.com Cristofanilli M, et al. SABCS 2015. Abstract P4-13-01.

PALOMA-3: Baseline Characteristics Baseline characteristics well balanced between arms; ~ 75% < 65 yrs of age Characteristic Palbociclib + Fulvestrant (n = 347) Placebo + Fulvestrant (n = 174) Median age, yrs (range) 57 (30-88) 56 (29-80) ER+ and PgR+, % 68.6 63.8 ER+ and PgR-, % 26.2 27.6 Sensitive to prior hormonal Tx, % 79.0 78.2 Metastatic disease at study entry, % 85.3 83.9 Prior AI ± GnRH agonist, % 67.8 Prior tamoxifen ± GnRH agonist, % 18.2 17.2 Prior neo/adjuvant chemotherapy, % 41.5 43.1 Prior lines of tx for metastatic disease, % 1 38.0 40.2 2 25.9 24.7 ≥ 3 11.8 9.2 AI, aromatase inhibitor; ER, estrogen receptor; GnRH, gonadotropin-releasing hormone; PgR, progesterone receptor; tx, treatment. Cristofanilli M, et al. SABCS 2015. Abstract P4-13-01. Turner NC, et al. N Engl J Med. 2015;373:209-219. Slide credit: clinicaloptions.com

PALOMA-3: PFS in Overall Population and Specific Pt Subgroups Median follow-up: 8.9 mos Median PFS, Mos (95% CI) Palbociclib + Fulvestrant (n = 345) Placebo + Fulvestrant (n = 172) HR (95% CI) P Value ITT population 9.5 (9.2-11.0) 4.6 (3.5-5.6) 0.45 (0.36-0.59) < .0001 Pre-/perimenopausal pts 9.5 (7.4-NE) 5.6 (1.8-7.6) 0.50 (0.29-0.87) .0065 Postmenopausal women 9.9 (8.5-11.0) 3.9 (3.5-5.5) 0.45 (0.34-0.59) No earlier systemic therapy for metastatic disease 5.4 (2.1-10.9) 0.55 (0.32-0.92) .0214 Disease responsive to earlier endocrine therapy 10.2 (9.4-11.2) 4.2 (3.5-5.6) 0.42 (0.32-0.56) AIs as most recent therapy 3.7 (3.4-5.5) 0.42 (0.31-0.56) AI, aromatase inhibitor; ITT, intent to treat; NE, not evaluable. Slide credit: clinicaloptions.com Cristofanilli M, et al. SABCS 2015. Abstract P4-13-01.

PALOMA-3: Response and Clinical Benefit Rates Median follow-up: 8.9 mos Outcome, % (95% CI) Palbociclib + Fulvestrant (n = 345) Placebo + Fulvestrant (n = 172) Odds Ratio (95% CI) P Value ITT population ORR CBR 19.0 (15.0-23.6) 66.6 (61.3-71.5) 8.6 (4.9-13.8) 39.7 (32.3-47.3) 2.47 (1.36-4.91) 3.05 (2.07-4.61) .0019 < .0001 Pts with measurable disease at BL 24.6 (19.6-30.2) NR 10.9 (6.2-17.3) 2.69 (1.43-5.26) 3.10 (1.99-4.92) .0012 BL, baseline; CBR, clinical benefit rate; ITT, intent to treat; NR, not reported. Slide credit: clinicaloptions.com Cristofanilli M, et al. SABCS 2015. Abstract P4-13-01.

Palbociclib + Fulvestrant Palbociclib + Fulvestrant PALOMA-3: Grade 3/4 AEs Nonhematologic AE, n Palbociclib + Fulvestrant (n = 345) Placebo + Fulvestrant (n = 172) Infections 6 1 Fatigue 8 Headache 2 Vomiting Decreased appetite 3 Rash Back pain 4 Arthralgia Stomatitis Dizziness Dyspnea Pyrexia Insomnia Hematologic Event, n (%) Palbociclib + Fulvestrant (n = 345) Placebo + Fulvestrant (n = 172) Neutropenia 223 (65) 1 (< 1) Anemia 10 (3) 3 (2) Leukopenia 93 (27) 2 (1) Thrombocytopenia 6 (2) Febrile neutropenia incidence was similar with palbociclib + fulvestrant and placebo + fulvestrant (0.9% vs 0.6%, respectively) Discontinuations due to AEs were similar with palbociclib + fulvestrant and placebo + fulvestrant (4% vs 2%, respectively) AE, adverse event. Slide credit: clinicaloptions.com Cristofanilli M, et al. SABCS 2015. Abstract P4-13-01.

PALOMA-3: Conclusions In pts with ER+/HER2- breast cancer that has progressed after endocrine therapy The significant improvement in efficacy with the addition of palbociclib to fulvestrant was maintained through longer follow-up Benefit demonstrated across all subgroups No new safety concerns were identified; certain hematologic AEs were more common with palbociclib than fulvestrant alone The incidence of febrile neutropenia was similar for both treatment arms AE, adverse event; ER, estrogen receptor. Slide credit: clinicaloptions.com Cristofanilli M, et al. SABCS 2015. Abstract P4-13-01.

Go Online for More CCO Coverage of SABCS 2015! Short slideset summaries of all the key data Additional CME-certified slideset on breast cancer with expert faculty commentary on all the key studies clinicaloptions.com/oncology